Several challenges exist, including the complexity of tumor biology, interpatient variability, and the potential for drug resistance. Tumors can create unique microenvironments that affect drug absorption and distribution. Additionally, genetic differences among patients can lead to varied metabolic and excretory responses, complicating treatment standardization.
